Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation

American Heart Journal

Volumn 141, Issue 1, 2001, Pages 124-130

  Kozuma, Ken ^a   Hara, Kazuhiro ^b   Yamasaki, Masao ^b   Morino, Yoshihiro ^b   Ayabe, Seiji ^b   Kuroda, Yuzo ^b   Tanabe, Kengo ^b   Ikari, Yuji ^b   Tamura, Tsutomu ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY STENT; DEATH; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RASH; RESTENOSIS; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0035161371     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.111548     Document Type: Article

References (35)

1. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators
2. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group
3. Stents currently available
4. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance
5. Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions
6. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: Six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial
7. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: A multicenter, randomized study comparing two strategies - With and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting
8. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
9. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
10. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography
11. Effect of cilostazol on platelet aggregation and experimental thrombosis
12. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
13. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen
14. Comparison of cilostazol versus ticlopidine therapy after stent implantation
15. Antiplatelet treatment with cilostazol after stent implantation
16. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
17. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture
18. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: An experimental study
19. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
20. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation
21. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis
22. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
23. Variations in measured vessel diameters using coronary measurement system
24. Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems
25. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting
26. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis
27. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study
28. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells
29. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells
30. Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats
31. Impact of cilostazol on intimal proliferation after directional coronary atherectomy
32. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
33. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
34. Predictors of restenosis after coronary stent implantation
35. Predictive factors of restenosis after coronary stent placement